India, Nov. 17 -- Biogen (BIIB) presented new Phase 2 data showing that diranersen, an investigational therapy targeting the tau protein, continued to slow disease progression in people with early Alzheimer's disease over two years of treatment.

Alzheimer's disease is a progressive neurological disorder that gradually affects memory, thinking and daily functioning. Slowing the rate of decline may help patients maintain independence for longer periods.

Results from the Phase 2 CELIA study, presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference, showed that the 60 mg twice-yearly dose of diranersen slowed clinical decline by 38% on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at two years compared with patients who ...